A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

BACKGROUND: To examine the angiopoietin pathway inhibitor trebananib IV plus the anti-VEGF agents bevacizumab or motesanib in advanced solid tumours. METHODS: In this open-label phase 1b study, patients received IV trebananib 3 mg kg(−1) QW plus bevacizumab 15 mg kg(−1) Q3W (cohort 1) or motesanib o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Kurzrock, Razelle, Mulay, Marilyn, Rasmussen, Erik, Wu, Benjamin M., Bass, Michael B., Zhong, Zhandong D., Friberg, Greg, Rosen, Lee S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294348/
https://www.ncbi.nlm.nih.gov/pubmed/25525888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294348/
https://www.ncbi.nlm.nih.gov/pubmed/25525888

Ejemplares similares